Susquehanna International Group
TXMD icon

Susquehanna International Group’s TherapeuticsMD TXMD Stock Holding History

Susquehanna International Group’s Portfolio TXMD Stock Details TXMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$42.9K Sell
21,220
-13,944
-40% -$31.4K ﹤0.01% 12674
2025
Q4 		$57.3K Buy
+35,164
New +$50.8K ﹤0.01% 11707
2023
Q1 		– Sell
-82,877
Closed -$398K – 13522
2022
Q4 		$463K Buy
82,877
+10,114
+14% +$59.5K ﹤0.01% 8075
2022
Q3 		$483K Buy
72,763
+35,516
+95% +$288K ﹤0.01% 8586
2022
Q2 		$371K Buy
37,247
+30,420
+446% +$290K ﹤0.01% 8985
2022
Q1 		$130K Sell
6,827
-7,294
-52% -$115K ﹤0.01% 11706
2021
Q4 		$251K Sell
14,121
-11,547
-45% -$346K ﹤0.01% 10928
2021
Q3 		$952K Buy
25,668
+2,409
+10% +$107K ﹤0.01% 7688
2021
Q2 		$1.38M Sell
23,259
-14,272
-38% -$865K ﹤0.01% 6869
2021
Q1 		$2.52M Buy
37,531
+22,889
+156% +$1.79M ﹤0.01% 5364
2020
Q4 		$886K Buy
14,642
+7,606
+108% +$519K ﹤0.01% 6993
2020
Q3 		$556K Sell
7,036
-8,158
-54% -$650K ﹤0.01% 7452
2020
Q2 		$950K Buy
15,194
+2,712
+22% +$158K ﹤0.01% 6049
2020
Q1 		$662K Sell
12,482
-1,926
-13% -$191K ﹤0.01% 6328
2019
Q4 		$1.74M Sell
14,408
-8,030
-36% -$1.15M ﹤0.01% 4559
2019
Q3 		$4.07M Buy
22,438
+17,512
+356% +$2.47M ﹤0.01% 3007
2019
Q2 		$640K Sell
4,926
-4,932
-50% -$884K ﹤0.01% 6730
2019
Q1 		$2.4M Sell
9,858
-203
-2% -$53.7K ﹤0.01% 3471
2018
Q4 		$1.92M Sell
10,061
-15,687
-61% -$3.83M ﹤0.01% 3588
2018
Q3 		$8.45M Buy
25,748
+15,876
+161% +$4.86M ﹤0.01% 2115
2018
Q2 		$3.08M Buy
9,872
+992
+11% +$303K ﹤0.01% 3348
2018
Q1 		$2.16M Sell
8,880
-1,174
-12% -$329K ﹤0.01% 3768
2017
Q4 		$3.04M Sell
10,054
-10,509
-51% -$2.93M ﹤0.01% 3220
2017
Q3 		$5.44M Buy
20,563
+14,481
+238% +$4.19M ﹤0.01% 2394
2017
Q2 		$1.6M Sell
6,082
-3,473
-36% -$870K ﹤0.01% 4314
2017
Q1 		$3.44M Sell
9,555
-2,282
-19% -$706K ﹤0.01% 2826
2016
Q4 		$3.42M Buy
+11,837
New +$3.67M ﹤0.01% 3020
2016
Q2 		– Sell
-757
Closed -$312K – 9349
2016
Q1 		$242K Sell
757
-886
-54% -$302K ﹤0.01% 7629
2015
Q4 		$852K Sell
1,643
-3,234
-66% -$1.19M ﹤0.01% 5742
2015
Q3 		$1.43M Buy
4,877
+2,741
+128% +$974K ﹤0.01% 4980
2015
Q2 		$839K Buy
2,136
+1,135
+113% +$400K ﹤0.01% 6583
2015
Q1 		$303K Sell
1,001
-87
-8% -$21.2K ﹤0.01% 7964
2014
Q4 		$242K Buy
1,088
+506
+87% +$104K ﹤0.01% 8492
2014
Q3 		$135K Sell
582
-324
-36% -$81.6K ﹤0.01% 8955
2014
Q2 		$200K Buy
+906
New +$202K ﹤0.01% 9075
2014
Q1 		– Sell
-3,563
Closed -$928K – 9458
2013
Q4 		$928K Buy
+3,563
New +$780K ﹤0.01% 5640

Other funds holding TXMD

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $273M AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Susquehanna International Group's TXMD Position: Q1 2026 in Review

Susquehanna International Group reduced its TherapeuticsMD (TXMD) stake by 40% in Q1 2026, selling an estimated $31.4K and leaving 21,220 shares worth $42.9K. The position accounts for ﹤0.01% of the portfolio, ranked #12674.

Susquehanna International Group first reported a position in TXMD in Q4 2013 and has held it in 36 quarters since. The position peaked at $8.45M in Q3 2018. 49 funds tracked by Wall St. Rank hold TXMD as of Q1 2026.

  • Susquehanna International Group held 21,220 shares of TherapeuticsMD worth $42.9K as of Q1 2026.
  • Susquehanna International Group sold 13,944 TherapeuticsMD shares in Q1 2026, an estimated $31.4K.
  • TherapeuticsMD made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #12674 holding.
  • Susquehanna International Group first reported a position in TherapeuticsMD in Q4 2013 and has held it in 36 quarters since.
  • Susquehanna International Group's TherapeuticsMD position peaked at $8.45M in Q3 2018.
  • 49 funds tracked by Wall St. Rank held TherapeuticsMD as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.